Ovid Hosts Conference Call to Discuss Strategic Transaction Mar 3, 2021 8:30 AM EST Click here for webcast
Press Releases Year None2021202020192018201720162015 Apr 20, 2021 Ovid Therapeutics Announces Appointment of Professor Robert S. Langer, Sc.D., as Chair of its Scientific Advisory Board Apr 19, 2021 OVID Provides Update on OV101 Program and the Prioritization of its Resources Mar 30, 2021 Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat Mar 15, 2021 Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021 Mar 03, 2021 Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
